🔍 Are 2025 ASAS-SPARTAN criteria valid in early axSpA?

      SPACE cohort (n=669):

      HIGH specificity (97.5%) but LOWER s

      Nelly ZIADE 🍀 Nellziade

      1 week ago
      🔍 Are 2025 ASAS-SPARTAN criteria valid in early axSpA? SPACE cohort (n=669): HIGH specificity (97.5%) but LOWER sensitivity (60%) vs 2009 criteria (83%) #OP0239 #EULAR2026 @RheumNow https://t.co/9wNbtcbP0l
      A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology

      EULAR launches a Study Group on

      Dr. John Cush RheumNow

      1 week ago
      A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology EULAR launches a Study Group on Geriatric Rheumatology — clinics increasingly serve older patients with multimorbidity, polypharmacy, frailty, cognitive and functional limits, yet research
      Window of opportunity in stills disease is early. With IL1 / IL6 agents
      #sJIA and #AOSD are the same disease. - may need

      Bella Mehta bella_mehta

      1 week ago
      Window of opportunity in stills disease is early. With IL1 / IL6 agents #sJIA and #AOSD are the same disease. - may need a standard new crieteria IL18 measuremnet should be encouraged. @RheumNow #EULAR2026 plenary https://t.co/EQbs9mDYjS
      Transitioning from pediatrics to adult rheumatology for patients with autoinflammatory disease such as #AOSD should be d

      Bella Mehta bella_mehta

      1 week ago
      Transitioning from pediatrics to adult rheumatology for patients with autoinflammatory disease such as #AOSD should be done with administrative support and the right hand off. @RheumNow #EULAR2026 plenary talk https://t.co/N8qB7jrZfM
      🔬 Can filgotinib improve axSpA?

      OLINGUITO (Phase 3 RCT, n=495):

      YES! ASAS40 39.5% vs 21% (r-axSpA) at week 16

      #O

      Nelly ZIADE 🍀 Nellziade

      1 week ago
      🔬 Can filgotinib improve axSpA? OLINGUITO (Phase 3 RCT, n=495): YES! ASAS40 39.5% vs 21% (r-axSpA) at week 16 #OP0234 #EULAR2026 @RheumNow https://t.co/0vj2KqSS1b
      EULAR flags
      Vasculitis Updates: Glucocorticoid use in AAV and GCA
      • 2026 EULAR Press Release
      1 week ago
      Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs. EULAR has recommendations that cover glucocorticoid use in ANCA associated vasculitides (AAV) and large vessel vasculitis, including giant cell arteritis (GCA).1,2 But the evidence base continues to grow about their use – especially over the long term.
      What defines MRI indicative of axSpA?

      This systematic lit review show adapting more stringent cutoffs in BME (>=4 S

      sheila RHEUMarampa

      1 week ago
      What defines MRI indicative of axSpA? This systematic lit review show adapting more stringent cutoffs in BME (>=4 SIJ quads, erosion >=3 quads, fat >=5 SIJ quads) & combined BME + structural lesions inc specificity. Time for updated definitions? AbsPOS0866 @RheumNow #EULAR2026 https://t.co/gkVbcOAiD3
      @RheumNow WIN Nutrition session #EULAR2026 (4)
      🌾 Gluten does NOT influence biologic response in RD, BELIEVE cohort, 1

      Nelly ZIADE 🍀 Nellziade

      1 week ago
      @RheumNow WIN Nutrition session #EULAR2026 (4) 🌾 Gluten does NOT influence biologic response in RD, BELIEVE cohort, 197 pts. No need to go gluten-free unless celiac disease 🌱 Plants for Joints trial: plant-based diet + exercise → sustained DAS28&WOMAC improvement @ 2Y, RA/OA @RheumNow
      @RheumNow WIN Nutrition session at #EULAR2026 (3)
      6.🍟 High UPF intake → increased RA risk (HR 1.06/SD), partly medi

      Nelly ZIADE 🍀 Nellziade

      1 week ago
      @RheumNow WIN Nutrition session at #EULAR2026 (3) 6.🍟 High UPF intake → increased RA risk (HR 1.06/SD), partly mediated by CRP. Not all NOVA-4 foods are equal 7.💊 Vit D supplementation significantly reduces SLE disease activity — MA of 10 RCTs, SMD −0.54 (p<0.00001). @RheumNow
      WIN Nutrition session at #EULAR2026 (2)
      🐟 n-3 PUFAs reduce RA risk by 9–10% per SD increase — especially in gen

      Nelly ZIADE 🍀 Nellziade

      1 week ago
      WIN Nutrition session at #EULAR2026 (2) 🐟 n-3 PUFAs reduce RA risk by 9–10% per SD increase — especially in genetically high-risk individuals. 🫒 Mediterranean diet reduces RA risk by 25% (HR 0.75) & SLE risk by 39% (HR 0.61) in UK Biobank studies. @RheumNow
      WIN Nutrition session at #EULAR2026 (1)

      🫐Higher fruit intake → RR 0.88 & cereal intake → RR 0.87 for RA onse

      Nelly ZIADE 🍀 Nellziade

      1 week ago
      WIN Nutrition session at #EULAR2026 (1) 🫐Higher fruit intake → RR 0.88 & cereal intake → RR 0.87 for RA onset 🥩 Highest quartile of red & processed meat intake → nearly DOUBLE the risk of RA onset (OR 1.92, CI 1.11–3.35) @rheumnow https://t.co/RhO08FXtLI
      Impt pts to consider in D2T CLE by Prof Wittmann:
      If tx is not working, ask yourself: is the dx correct? adherence?
      Mai

      sheila RHEUMarampa

      1 week ago
      Impt pts to consider in D2T CLE by Prof Wittmann: If tx is not working, ask yourself: is the dx correct? adherence? Main message: treat early When damage is present, tx doesn’t really provide considerable improvements Future drxns? Endotype-directed tx @Rheumnow #EULAR2026 https://t.co/hB48aD7jx5
      Metaflammation !! A new term I learnt at #EULAR2026 plenary. @RheumNow
      Inflammation triggered by metabolic abnormalities

      Bella Mehta bella_mehta

      1 week ago
      Metaflammation !! A new term I learnt at #EULAR2026 plenary. @RheumNow Inflammation triggered by metabolic abnormalities. This may be the reason a lot of our inflammatory arthritis patients on GLP1 drugs(other indications) have thier disease activities improving. Emerging data.
      #OP0239: validating 2025 ASAS-SPARTAN axSpA classification criteria in the SPACE cohort. Revised criteria showed high sp

      Mrinalini Dey DrMiniDey

      1 week ago
      #OP0239: validating 2025 ASAS-SPARTAN axSpA classification criteria in the SPACE cohort. Revised criteria showed high specificity but lower sensitivity than 2009 criteria, reflecting greater emphasis on imaging & less reliance on clinical features alone. #EULAR2026 @RheumNow
      Catching your breath session at #EULAR2026

      RA-ILD is heterogeneous, maybe under-recognized and risk stratification rema

      Jiha Lee JihaRheum

      1 week ago
      Catching your breath session at #EULAR2026 RA-ILD is heterogeneous, maybe under-recognized and risk stratification remains a challenge (Pierre-Antoine -Jugr) Screening for RA-ILD is only as good as availability of early intervention and treatment (Jeff Sparks) @RheumNow https://t.co/V1JXM3i9wP

      Podcasts

      • Day 4 Recap EULAR 2026

      Catch up on Conference Podcasts

      ×